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Parkinson’s disease (PD) is a neurodegenerative disease with the pathological hallmark
of reduced nigrostriatal dopamine. In traditional Chinese medicine (TCM) clinical
practice, the nanopowder of Cistanche tubulosa has therapeutic effects on PD. To
identify the therapeutic mechanism, this study tested the protective effect of different
doses of MPP+-induced toxicity in MES23.5 cells using the MTT assay and in
the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced PD mice (vehicles).
Immunohistochemistry was used to assess cytomorphology and tyrosine hydroxylase
(TH) expression. Behavioral tests in vehicles, high performance liquid chromatography
(HPLC) tests in dopamine, immunohistochemistry and western blot analysis were used
to detect the expression of TH, glial cell line-derived neurotrophic factor (GDNF) and
its receptors. Our results demonstrated that the C. tubulosa nanopowder improved the
viability of MPP+-treated cells, increased TH expression and reduced the number of
apoptotic cells. It also increased Bcl2 protein expression and suppressed Bax protein
expression in MPP+-treated cells in a dose-dependent manner. In addition, C. tubulosa
nanopowder improved the behavioral deficits in vehicle mice, reduced the stationary
duration of swimming, enhanced the ability for spontaneous activity and increased
the expression of GDNF, the GDNF family receptor alpha (GFRα1) and Ret in cells of
the substantia nigra (SN). Furthermore, the protein expression of GDNF, GFRα1 and
Ret increased after treatment with different doses of C. tubulosa nanopowder, with a
significant difference between the high-dose and vehicle groups. The protein expression
of Bcl2 and Bax were similar in the in vivo and in vitro, which suggested that C. tubulosa
nanopowder has anti-apoptotic effects in neurons.
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INTRODUCTION
Parkinson’s disease (PD) is a common neurodegenerative disease occuring in elderly people with
the pathological manifestations of loss of dopaminergic neurons in the substantia nigra (SN)
due to degeneration. The severity of the disease has been shown to be correlated with dopamine
(DA) neuronal cell loss in the SN, which is consistent with the view that the neurodegenerative
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process progresses over many years before any symptoms appear
(Sawle and Myers, 1993). The progressive nature of the disease
suggests interesting possibilities for therapeutic intervention by
blocking the underlying neurodegenerative process. The search
for therapy-induced potent and specific actions of neurotrophic
factors on DA neuron survival is therefore of considerable
interest.
Neurotrophic factors are essential proteins, including nerve
growth factor (NGF), brain derived neurotrophic factor (BDNF)
and glial cell-derived neurotrophic factor (GDNF), which
promote nerve growth, neurological development, axonal
guidance and neuronal function. Among all of the neurotrophic
factors that protect and promote the repair of dopaminergic
neurons, GDNF has the strongest effects (Hong et al., 2008;
Rangasamy et al., 2010; Allen et al., 2013). GDNF has been
shown to possess potent neurotrophic effects on DA neurons
in vitro (Lin et al., 1993) and to exert neuroprotective effects
in vivo. GDNF has been shown to rescue nigral DA neurons
from lesion-induced cell death after surgical- or toxin-induced
axotomy in rats (Beck et al., 1995; Kearns and Gash, 1995; Sauer
et al., 1995) and partially also after systemic administration of
N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in mice
(Tomac et al., 1995). The increased incidence of neuronal
apoptosis and reduced protective effects of neurotrophic factors,
potentially triggered by various pathological factors, underlie
the degeneration of dopaminergic neurons (Holden et al.,
2006).
C. tubulosa is an herbal medicine originating from several
plants of the genus Cistanche. It is a major therapeutic option
for kidney deficiency syndrome which is closely related to
androgen hormones in traditional Chinese medicine (TCM).
To date, lots of clinical and basic research of C. tubulosa
have showed the activities on neurodegenerative diseases. The
identification of TCM kidney-tonifying prescriptions in PD
treatment may thus provide an alternative clinical treatment
for PD. Echinacoside (ECH) is a major bioactive component
found in the medicinal herb C. tubulosa. Studies have shown
the therapeutic effects of glycosides of Cistanche and ECH,
verbascoside (VER) and icariin (ICA) on Alzheimer’s disease
(AD), PD and other vascular dementia patients (Urano and
Tohda, 2010; Wang et al., 2013; Wu et al., 2014). Wu et al. (2014)
suggested that C. tubulosa extracts that contained enough ECH
and acteoside ameliorated the cognitive dysfunction caused by
Aβ-42 via blocking amyloid deposition, and reversing cholinergic
and hippocampal dopaminergic neuronal function. Tao et al.
(2015) found that phenylethanoid glycosides from C. tubulosa
(Ph Gs-Ct) prevented high altitude cerebral edema by decreasing
the protein and mRNA expression of AQP4 in the brain tissue of
rat models.
Previous studies have shown that Chinese herbal compounds,
including the three ingredients of C. tubulosa, epimedium
and rhizoma polygonati, alleviated damage to dopaminergic
neurons and increased levels of dopamine by regulating
the expression of neurotrophic factors (Wu et al., 2013).
Thus, it is not yet known whether the C. tubulosa-induced
neuroprotective effects are long-lasting and to what extent
rescue of nigral DA neurons by administration of GDNF can
afford significant preservation of motoric behaviors of relevance
for the symptomatology of PD animal. This study used a
TCM kidney-tonifying recipe, C. tubulosa nanopowder, that
has received a national patent (patent number: 2011103028541)
in China and has previously shown a certain therapeutic
effect in PD. The present study, therefore, was designed
to examine the neuro-protective and regenerative effects
of C. tubulosa treatment and to investigate the apoptosis
on the MES23.5 cells and behavioral deficitive rats, and
the regulation of GDNF, as measured by a battery of
target tests.
MATERIALS AND METHODS
Materials, Reagents and Equipment
C. tubulosa was purchased from Beijing Tong Ren Tang Group,
Co., Ltd., Beijing, China. ECH, VER and ICA came from
the National Institutes for Food and Drug Control, China.
The MES23.5 dopaminergic neuronal cell line was a gift from
Professor Biao Chen, Laboratory of Neurobiology, Capital
Medical University, Beijing, China. Fifty C57BL/6 male mice
(weighing 20–25 g each) were purchased from Shanghai SLAC
Laboratory Animal Co., Ltd. (license number: SCXK2012-0002),
Shanghai, China.
MPP+, MTT and glutamine were purchased from Sigma-
Aldrich (Carlsbad, CA, USA); DMEM/F12 medium and
fetal bovine serum were purchased from Gibco Co. (Life
Technologies, Carlsbad, CA, USA); and MPTP, DA standard
and homovanillic acid (HVA) standard were purchased
from Sigma-Aldrich (Carlsbad, CA, USA). β-actin, Bax,
Bcl2, GDNF, GDNF family receptor alpha (GFRα1) and Ret
antibodies were purchased from Cell Signaling Technology,
Inc. (Beverly, MA, USA); 3,3’-diaminobenzidine (DAB)
staining reagent kit was purchased from Fuzhou Maixin
Biotech., Ltd. (Fujian, China); and SDS-PAGE gel sample
preparation kit, ultrasensitive enhanced chemiluminescence
(ECL) detection kit and bicinchoninic acid (BCA) assay were
purchased from Beyotime Institute of Biotechnology (Beijing,
China).
This study used the following instruments:
ELX800 microplate reader (Bio Tek Winooski, VT, USA);
CO2 incubator (Heraeus, Hanau, Germany); Gel DOC 2000 gel
imaging analysis system, electrophoresis cell and electrophoresis
tank (Bio-Rad, Hercules, CA, USA); DU-650 protein analyzer
(Beckman Coulter, Inc., Fullerton, CA, USA); 5417R high-speed
refrigerated centrifuge (Eppendorf, Hamburg, Germany);
SXQM dual planetary ball mill (Changsha, Tencan Powder
Technology Co., Ltd, Hunan, China); MM400 mixer mill (Retsch
GmbH, Haan, Germany); Agilent 1200 high-performance
liquid chromatography (HPLC; Agilent Technologies, Santa
Clara, CA, USA); PowerPac Basic electrophoresis, PowerPac
Basic transmembrane transfer system, Universal Hood II
chemiluminescence imager, S1000 Thermal Cycler RNA reverse
transcription system (Bio-Rad); Motic Med 6.0 tissue and cell
image analysis system (Motic China Group, Co., Ltd, Xiamen,
China).
Frontiers in Aging Neuroscience | www.frontiersin.org 2 December 2016 | Volume 8 | Article 295
Xu et al. C. tubulosa Protects Dopaminergic Neurons
Preparation of C. tubulosa Nanopowder
C. tubulosa was weighed, then purified and dehydrated. After
conventional pulverization, C. tubulosa fine powder was passed
through a 200-mesh sieve and freeze-dried. A temperature-
controlled vacuum and high-energy ball mill was used to
prepare the C. tubulosa nanopowder. First, raw C. tubulosa
nanopowder was placed in a vacuum ball-milling tank that
was loaded with carbide grinding balls. The ratio between
the grinding balls and C. tubulosa nanopowder ranged from
15:1 to 5:1. To obtain a fine powder, the speed and duration
of the high-energy ball mill were set to 300 rpm and 20 min,
respectively. The fine powder was weighed for the processing
of nanoscale materials and processed in the mixer mill with a
frequency of 25/s and oscillation of 20 s for three repetitions.
PBS was used to dissolve and prepare a 25 mg/mL stock solution,
followed by 30 min of ultrasonication, autoclaving and finally
storage at−20◦C.
Quality Control of the Active Components
of C. tubulosa by HPLC
The ECH and VER contained gradient elution with
octadecylsilane-bonded silica as filler, methanol as mobile
phase A and 0.1% formic acid solution as mobile phase B.
The detection wavelength was 330 nm. The ICA contained
gradient elution with octadecylsilane-bonded silica as filler and
acetonitrile water (30:70) as the mobile phase. The detection
wavelength was 270 nm. The sample, control and negative
control were measured as 10 µL each for the test.
Cell Culture and MTT Assay to Measure
Viability of MPP+-Treated Cells
MES23.5 cells were inoculated with 5% fetal calf serum, 1%
glutamine, 2% 50× Sato’s solution and DMEM/F12 medium
with 2% penicillin/streptomycin. They were incubated at 37◦C
in a 5% CO2 incubator with saturated humidity. The cells
were isolated and passaged with 0.25% trypsin and the cell
suspension was harvested in the logarithmic growth phase.
Isolated cells with a density of 1 × 105 were seeded into
polylysine-coated 96-well plates, followed by the addition of
different final concentrations (6.25, 12.5, 25, 50, 100, 200, 400 and
800 µmol/L) of MPP+ media. MES23.5 cells that were incubated
with normal culture medium for 24 h and 48 h were used
as negative controls in the in vitro experiments. The cells
from the different treatment groups were incubated with MTT
reagent for 4 h. The solution in the wells was subsequently
discarded and 150 µL of DMSO was added and oscillated for
10 min. The absorbance of each sample at a wavelength of
570 nm was measured using an automatic microplate reader.
The percentage of cell viability (%) = mean absorbance of the
experimental group/mean absorbance of the negative control
group× 100%.
Relevant concentrations of MPP+ medium were added for
the 24 h treatment in MES23.5 cells using the same approach as
for the in vitro culture. After the treatment, the solution in the
well was discarded. Media containing different concentrations
(10, 50, 100, 200, 250, 500 and 1000 µg/mL) of C. tubulosa
nanopowder was added to the MES23.5 cells in different wells
and left to incubate for 24 h and 48 h. TheMES23.5 cells that were
incubated with normal culture medium for 24 h and 48 h were
used as negative controls. The MES23.5 cells that were incubated
withMPP+ mediumwere used as the vehicle. The measurements
were done in triplicate for each sample. The absorbance of the
corresponding treatment and control groups was measured to
calculate cell viabilities.
TH Expression Measured by
Immunocytochemistry
When C. tubulosa nanopowder was in 100, 200 and 250 µg/ml,
the cell survival rate increased significantly (Figure 2G). Thus,
in subsequent experiments, we tested the three concentrations:
low-dose, middle-dose and high-dose groups. Three replications
were tested for each of the C. tubulosa groups. Sterilized,
polylysine-coated coverslips were placed into 6-well plates. Next,
5 × 104 cells were seeded in each well and incubated for 24 h.
Conventional fresh medium was replaced in the normal control
group and a final concentration of 100 µmol/L MPP+ medium
was replaced in the remaining treatment groups to incubate
for 24 h. Conventional fresh media were then replaced in the
normal control and vehicle groups, and final concentrations of
100, 200 and 250µg/mL C. tubulosa nanopowder were incubated
with the cells for 24 h in the low-, moderate- and high-dose
C. tubulosa treatment groups, respectively. The MES23.5 cells in
the different groups were washed three times in PBS to remove
the supernatant and further fixed in 4% paraformaldehyde for
15 min. After washing with PBS, the cells were incubated with
a peroxidase blocker at 37◦C for 30 min and then washed
again with PBS. A 0.2% Triton X-100 solution was used for cell
permeabilization for 10 min, followed by a washing with PBS.
Normal goat serum was added to each sample and incubated
at room temperature for 30 min. The normal goat serum was
then removed and primary antibody diluted 1:400 in PBS was
added to each sample and incubated at 4◦C overnight. The cells
in the negative control group were incubated with PBS at 4◦C
overnight. After washing with PBS, the cells were incubated
with biotin-labeled secondary antibody in the moisture chamber
at 37◦C for 20 min. Each sample was then washed in PBS
and labeled with horseradish peroxidase-streptavidin conjugates
(working solution C) at 37◦C for 20 min. After washing with
PBS, the cells were stained with DAB reagent in the dark for
approximately 1–10 min and the development of a brown color
was monitored under light microscopy. Each sample was then
washed twice in distilled water for 1–2 min and the nuclei
were counterstained with hematoxylin solution for 0.5–1 min.
After thoroughly rinsing each sample in water, the cells were
immersed in 1% hydrochloric acid alcohol for differentiation and
1% aqueous ammonia, followed by thoroughly washing the cells
in water. The cells from each sample were then dehydrated in
70% ethanol for 2 min, 80% ethanol for 2 min, 90% ethanol for
2 min twice, 95% ethanol for 2 min twice and 100% ethanol for
2 min twice. The cells were then immersed in xylene solution
for 2 min twice and mounted on a glass slide with neutral
resins. Under light microscopy, each sample underwent image
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capturing and random selection of 5–10 effective visual fields to
determine the expression of selected proteins in dopaminergic
neurons indicated by the intensity of the brown particles
and to semi-quantify the protein content by its average gray
value.
Apoptosis Rate of MES23.5 cElls Measured
by Flow Cytometry
Adherent cells were washed once with PBS. For cell isolation, an
appropriate amount of EDTA-free trypsin solution was added
at room temperature and the solution was gently pipetted to
allow adherent cells to detach. Cell culture medium was then
added to stop the trypsinization. The mixture was transferred to
a new centrifuge tube and then centrifuged 5 min at 1500 rpm
to collect the isolated cells. After discarding the supernatant, the
cell pellet was gently resuspended using PBS and the cells were
counted. Approximately 1 × 105 to 5 × 105 resuspended cells
were centrifuged for 5 min at 1500 rpm and the supernatant was
discarded. Five microliters of Annexin V-FITC binding solution
was added to the cell pellet to gently resuspend the cells. Another
5 µL of Annexin V-FITC was added and mixed thoroughly.
Five microliters of propidium iodide solution were used for cell
staining by incubating at room temperature for 10 min shortly
before the flow cytometry.
Western Blot Analysis for in vitro
The cells were divided into normal group, MPP+ treatment
group, low-dose C. tubulosa treatment group, moderate-dose
C. tubulosa treatment group and high-dose C. tubulosa treatment
group. The expression of Bcl2 and Bax was measured in each.
A total of 1 × 105 cells per well in the 6-well plate were used
for modeling and treatment in each group before cell harvesting.
A mixed lysate, containing RIPA buffer, protease inhibitor and
phosphatase inhibitor, was added to lyse the cells for 30 min on
ice. After centrifugation, the supernatant was used for protein
analysis. The total protein was quantified using a BCA assay
and separated by 10% SDS-PAGE. The separated proteins were
transferred to a membrane and incubated with a 5% skim milk
blocking buffer at room temperature for 2 h. The membrane
was then incubated in primary antibody (Bcl-2 0.34 mg/ml, Bax
0.11 mg/ml, 1:200 dilution) at 4◦C overnight. After a washing
step, the membrane was incubated in a secondary antibody
(0.5 mg/ml, 1:5000 dilution) at 4◦C for 1 h and then in ECL
developer for 2min for conventional development. Quantity One
software was used for the semi-quantitative analysis of protein
expression.
Experimental Animal Modeling and Drug
Administration
Fifty specific-pathogen-free 8-week-old male mice were
randomly divided into five groups: a normal group, MPTP
treatment group (Vehicle), low-dose C. tubulosa treatment
group, moderate-dose C. tubulosa treatment group and
high-dose C. tubulosa treatment group. The animals were
housed at 20–22◦C with free access to food and water. The
mice in the normal group were intraperitoneally injected with
an equal volume of normal saline for seven consecutive days.
The mice in the other treatment groups were intraperitoneally
injected with MPTP (30 mg/kg/d) for seven consecutive days to
establish vehicles.
During PD modeling, the mice in the low-dose,
moderate-dose and high-dose C. tubulosa treatment groups
were intragastrically administered equivalent clinical volumes of
4 g/kg/d, 8 g/kg/d and 16 g/kg/d C. tubulosa nanopowder,
respectively, for 14 consecutive days. The mice in the
control and vehicle groups were intragastrically administered
equivalent volumes of normal saline for 14 consecutive
days. All experimental procedures were approved by the
Ethical Committee of Fujian University of TCM and were
performed according to the internationally accepted principles
for laboratory animal use and care. All efforts were made to
minimize animal suffering in this study.
Behavioral Tests
Swimming Test (Zhu et al., 2014)
The coordination of body movement in mice was measured by
Swimming test. Themice were individually placed in a water tank
(25 cm in height and 10 cm in diameter) containing 10 cm of
water and tested in a quiet environment to record their stationary
duration over 5 min.
Open Field Test (Kawai et al., 1998)
Locomotor activity was measured by using the Open field test.
The mice were tested in a quiet and dim lit environment and
individually placed in a 30 cm × 30 cm × 15 cm transparent
acrylic container with a 6 cm × 6 cm separation grid at the
bottom. The mice were given 10 min to adapt to the environment
and then the ambulation of the grid number and rearing
frequency of individual mice were measured five consecutive
times to obtain mean values.
Brain Tissue Sampling
Before tissue sampling, the mice were fed adlibitum with free
access to water and received drug intervention for 14 consecutive
days. Four mice in each group were selected and quickly
decapitated. The SN (Bregma: −2.75 mm −2.92 mm) from
each animal was isolated and placed on ice. Brain tissues were
rinsed with 0.9% ice-cold sodium chloride solution to remove
any blood and dried on filter paper before storing at −80◦C.
Four mice from each group were anesthetized intraperitoneally
and their chests opened. An infusion needle was then inserted
into the left ventricle of each animal. To remove blood in the
circulatory system, the right atrial appendage was cut and the
animal was infused with 4◦C normal saline until the liver turned
pale to ensure successive perfusion. Once the effluent of the
right atrium became clear, each animal was perfused with 4%
paraformaldehyde fixative. After the perfusion, the brain tissue
of each animal was then dissected carefully and post-fixed in 4%
paraformaldehyde for 24 h. Fixed brain tissues were then rinsed
under running water, dehydrated in a graded series of ethanol
solutions and cleared in xylene solution. This was followed by
paraffin immersion and embedding.
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Changes of DA Quantity Measured by
HPLC
The nanopowdered SN from each group were placed in an
ice bath containing 0.9% sodium chloride solution (1:9 ratio).
The brain tissue was homogenized using an ultrasonic cell
disruptor and centrifuged at 1200 rpm for 20 min at 4◦C to
obtain the supernatant. For HPLC, a Hypersil AA-ODS column
(2.1 mm × 200 mm, 5 µm) at 30◦C column temperature was
used. Fluorescence detection was performed at 280 nm λex and
340 nm λem. The injection volume was 10 µL.
Expression of TH, GDNF, GFRα1 and Ret
Detected by Immunohistochemistry
Paraffin sections (5 µm thick) of individual brain tissue were
isolated from each animal and placed in a 40◦C warm water
bath for flattening and adhering to glass slides. All of the
tissue slides were incubated in a 60◦C oven for 3–6 h, followed
by xylene dewaxing, gradient ethanol dehydration and antigen
retrieval by incubating in a citric acid buffer and heating
in a microwave for 20 min. The tissue slides were then
incubated in a 3% H2O2 solution at room temperature for
10 min. After being washed three times in PBS, the tissue slides
were incubated with normal serum in a closed chamber at
room temperature for 20 min. Immunohistochemical staining
was conducted according to the manufacturer’s instructions.
A Motic Med 6.0 image analyzer was used to calculate
the value of integrated optical density in the positively
stained cells.
Western Blot Analysis in Brain Tissues of
Mice
This study assessed the protein expression of tyrosine
hydroxylase (TH), GDNF, GFRα1, Ret, Bcl2 and Bax. The
brain lysate from each group was homogenized for 30 min on
ice, followed by low temperature centrifugation, 20,000 rpm, at
4◦C for 5 min to collect the supernatant. The protein samples
were separated under constant pressure using a 10% SDS-PAGE
gel as described above. The primary antibody concentration:
TH 0.15 mg/ml, GDNF 0.5 mg/ml, GFRα1 0.8 mg/ml, Ret
0.63 mg/ml, Bcl-2 0.34 mg/ml and Bax 0.11 mg/ml. The
procedure was same as above.
Statistical Analysis
This study used SPSS 20.0 statistical software for data
processing and analysis. Parameter values were expressed as
mean± standard deviation (x¯ ± S). ANOVA was used for single
factor data analysis. LSD or Games-Howell test was used to
compare the groups. P < 0.05 (or P < 0.01) was considered as
a statistically significant difference.
RESULTS
The Active Components of C. tubulosa
Nanopowder
In the range of 200–400 nm scanning, ECH in C. tubulosa
and VER in 330 nm had the maximum absorption peak, which
appeared within 20 min. ICA had maximum absorption peaks
FIGURE 1 | Active components of C. tubulosa nanopowder. Scanning wavelength of maximum absorption peak ((A-A) echinacoside (ECH); (A-B)
verbascoside (VER); (A-C) icariin (ICA)) (A); (B-A) mixed standard sample; (B-B) C. tubulosa negative sample; (B-C) Epimedium negative sample; (B-D) C. tubulosa
nanopowder; 1: ECH; 2: VER; 3: ICA (B).
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FIGURE 2 | Effect of C. tubulosa nanopowder on cytomorphology of MPP+-damaged MES23.5 cells. The morphology of MES23.5 cells (A: control;
B: vehicle; C: low-dose; D: middle-dose; E: high-dose). Effect of different concentrations of MPP+ treatment on viability of the MES23.5 cell line (F). Effect of
different concentrations of C. tubulosa nanopowder on viability of MPP+-treated MES23.5 cells (G). Compare with the Vehicle: ∗∗P < 0.01; ∗P < 0.05; “n.s.” means
no significance. n = 3.
at 270 nm and appeared after 20 min (Figure 1A). The results
showed that the negative samples did not interfere with the
detection (Figure 1B). The samples and control had the same
chromatographic peaks and the negative sample had none. This
showed that the other ingredients in the sample did not interfere
with the component being measured. Moreover, the three
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components and the adjacent peaks can reach the separation
baseline and the separation degree was greater than 1.5.
C. tubulosa Nanopowder Reduced
MPP+-Induced Cytotoxicity in
MES23.5 Cells
The viability of MES23.5 cells was significantly reduced with
increasing concentrations of MPP+. Figure 2F shows the
significant cytotoxicity of different concentrations of MPP+.
C. tubulosa nanopowder reduced MPP+-induced cytotoxicity
and enhanced the viability of MES23.5 cells. Figure 2G
shows that C. tubulosa nanopowder dosages of 10–250 µg/mL
exerted dose-dependent protective effects on the MPP+-treated
MES23.5 cells.
Cytomorphological Effect of C. tubulosa
Nanopowder
Normal MES23.5 cells had good cell adhesion and were spindle
shaped with clear cell boundaries and synapses. MPP+-damaged
MES23.5 cells displayed poor cell adhesion and shrinkage,
and many were suspended in the media with contracted
synapses. These cells were aggregated, shrunken and round
with vacuoles inside, and the nuclei were disintegrated or
collapsed.C. tubulosa nanopowder in different dosages improved
the cytomorphology of MES23.5 cells in different degrees by
improving cell adhesion and synaptic clearance of the vehicle
group. MES23.5 cells in the high-dose C. tubulosa treatment
group showedmorphology that was similar to the normal control
group (Figures 2A–E).
Effect of C. tubulosa Nanopowder on TH
Expression and Apoptosis in the Cells
Figure 3 shows a significant reduction in the TH protein
expression in the vehicle group. The TH protein expression
increased differently in groups treated with different
dosages of C. tubulosa. However, LSD test showed there
was no significant difference between the three treated
groups.
Figure 4 shows the results of the apoptosis assessment
using flow cytometry. The rate of apoptosis in the vehicle
group was significantly higher than in the other groups. Cells
treated with different dosages of C. tubulosa nanopowder
showed different degrees of decline in the apoptotic rate
compared with the vehicle group. Cells in the middle-
and high-dose C. tubulosa treatment group had the most
significant improvement in apoptotic rate compared with
the other C. tubulosa treatment groups. LSD test showed
there was no significant difference between the two treated
groups but a significant different between the low-dose group
to them.
Effect of C. tubulosa Nanopowder on
Bcl2/Bax Protein Expression in the Cells
Figure 5 shows that the expression of Bcl2 protein in the cells
of the vehicle group was significantly lower compared with
the normal control group. In contrast, the expression of Bax
protein in cells of the vehicle group was significantly higher
than in the normal control group. C. tubulosa treatment groups
showed increased Bcl2 protein expression and decreased Bax
protein expression in MPP+-treated MES23.5 cells. Between
three treated goups there were significant differences by LSD test.
These effects were dose-dependent.
Behavioral Tests
The results of the Swimming test suggested that the mice in
the vehicle group had relatively long stationary durations, which
increased over time. At day 14, the mice in the vehicle group
had a significantly longer stationary duration than the mice in
the normal control group. The stationary duration of the mice in
FIGURE 3 | Effect of C. tubulosa nanopowder on tyrosine hydroxylase (TH) in MPP+-damaged MES23.5 cells (400×). The TH expression of MES23.5 cells
by immunocytochemistry (A: negative control; B: control; C: vehicle; D: low-dose (100 µg/ml); E: middle-dose (200 µg/ml); F: high-dose (250 µg/ml)). Compare with
the Vehicle: ∗∗P < 0.01. n = 3 (G).
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FIGURE 4 | Effect of C. tubulosa nanopowder on MPP+-induced apoptosis in MES23.5 cells. (A) control; (B) vehicle; (C) low-dose (100 µg/ml);
(D) middle-dose (200 µg/ml); (E) high-dose (250 µg/ml). UL: Upper Left (debris and damaged cells); UR: Upper Right (late apoptosis cells); LL: Lower Left (normal
cells); LR: Lower Right (early apoptotic cells) (A–E). Apoptosis rate = the number of (UR + LR) cells/total cell × 100%. Compare with the Vehicle: ∗∗P < 0.01;
∗P < 0.05. n = 3 (F).
the low-dose C. tubulosa treatment group was not significantly
different from that of the mice in the vehicle group. However,
the stationary duration of the mice in the high-dose C. tubulosa
treatment group was significantly less than that of the mice in the
vehicle group.
The results of the Open field test suggest that after
MPTP-induced damage in the mice, the mice in the
vehicle group demonstrated a significant decline in
their ability for spontaneous activity as shown by the
rearing frequency. After a 14-day administration of
C. tubulosa nanopowder, the mice in the moderate- and
high-dose treatment groups had significantly higher rearing
frequencies compared with the mice in the vehicle group
(Figures 6A,B).
FIGURE 5 | Effect of C. tubulosa nanopowder on Bcl2/Bax protein expression in MPP+-treated vehicle MES23.5 cells. The Bcl2 and Bax protein
expression in MES23.5 cells (A). The column charts of Bcl2 and Bax protein expression in MES23.5 cells (B,C). Compare with the Vehicle: ∗∗P < 0.01. n = 3.
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FIGURE 6 | Effect of Cistanche tubulosa nanopowder on the behavior and the dopamine content of the vehicle mice induced by
N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). The stationary duration of swimming in Swimming test (A). The number of rearing in Open field test (B).
The dopamine content (C). Compare with the Vehicle: ∗∗P < 0.01; ∗P < 0.05; “n.s.” means no significance. n = 3.
Effect of C. tubulosa Nanopowder on DA
Content in Mice
Changes in the DA content of the SN were determined by
HPLC. It was found that the DA content in the brain of the
vehicle group was significantly reduced. The DA content in the
brains of PD mice in the low-dose C. tubulosa treatment group
did not differ significantly from the mice in the vehicle group.
However, C. tubulosa treatment increased the DA levels in the
brains of PD mice in a dose-dependent manner. The brains of
PD mice treated with high-dose C. tubulosa had a significantly
higher DA content than the brains of mice in the vehicle group
(Figure 6C).
Effect of C. tubulosa Nanopowder on TH
Expression in Mice
The number of TH-positive cells and the level of TH protein
expression in the SN of MPTP-induced PD mice were lower
compared with mice in the control group. After the C. tubulosa
treatment, the number of TH-positive cells and the level of
TH protein expression in the SN of MPTP-induced PD mice
FIGURE 7 | Expression and integrated optical density of TH-positive cells in the substantia nigra (SN) in different treatment groups of mice (400×).
The TH-positive cells in the SN in different treatment groups of mice (400×) (A–F) (A) Negative control; (B) Control; (C) Vehicle; (D) Low-dose; (E) Middle-dose; (F)
High-dose. Integrated optical density of TH-positive cells in different treatment groups of mice (G). Protein expression of TH (H,I). Compare with the Vehicle:
∗∗P < 0.01; ∗P < 0.05. n = 3.
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increased, with a significant difference between the high-dose
C. tubulosa treatment group and the vehicle group by LSD test;
and there were significant differences between the three treated
groups (Figure 7).
Effect of C. tubulosa Nanopowder on
Protein Expression of GDNF and its
Receptors, GFRα1 and Ret in Mice
The protein expression of GDNF and its receptors, GFRα1 and
Ret, in the positively stained cells, was evaluated using
immunohistochemistry. Western blot analysis was used to
evaluate the protein expression levels in the SN of the different
groups of mice. The findings for the different groups were
similar using the two detection methods. The expression of
GDNF and its receptor proteins, GFRα1 and Ret, in positively
stained cells in the SN of the mice in the vehicle group
was significantly lower than in the mice in the normal
control group. Different dosages of C. tubulosa treatment
increased the number of GDNF-, GFRα1- and Ret-positive cells
(Figures 8A–S).
The protein expression of GDNF, GFRα1 and Ret in the SN of
the mice in the vehicle group was significantly lower than in the
mice in the control group. Increasing treatment concentrations
of C. tubulosa nanopower significantly enhanced the expression
of these proteins. The protein expression of GDNF, GFRα1 and
Ret in the SN of the mice in the high-dose C. tubulosa treatment
group was significantly higher than in the mice in the vehicle
group (P < 0.01; Figures 8T,U).
Effect of C. tubulosa Nanopowder on
Protein Expression of Bcl2/Bax in Mice
Bcl2 protein expression was significantly reduced and Bax
protein expression was significantly enhanced in the SN of
mice in the vehicle group (P < 0.01) compared with the mice
in the normal control group. High-dose C. tubulosa treatment
significantly increased Bcl2 protein expression and significantly
reduced Bax protein expression in the brains of the vehicle mice
(P < 0.01; Figure 9). LSD test showed there was no significant
difference between the middle-dose and high-dose groups but a
significant different between the low-dose group to them.
DISCUSSION
PD and Apoptosis
PD is a neurodegenerative disorder. According to Zhang et al.
(2005), the prevalence is 10.7% in the Chinese population aged
over 55 and 1.67% in those aged over 65. The number of PD
patients has increased annually with the acceleration of global
aging, placing a heavy financial burden on the families of patients
and society at large.
In the brain, dopaminergic neurons are mainly involved in
the synthesis and secretion of DA. They are widely distributed
in the central nervous system and located primarily in the SN
(80%). TH is the key rate-limiting enzyme for DA synthesis.
Thus, the inhibition of TH activity reduces DA synthesis
(Huot and Parent, 2007). Themain pathological and biochemical
changes of PD are apoptosis of dopaminergic neurons in the SN,
a significant reduction of nigrostriatal DA and the formation
of Lewy bodies in dopaminergic neurons (Dexter and Jenner,
2013). The etiology of PD involves associated genetic factors,
environmental factors and aging of the nervous system (Allam
et al., 2005). The pathogenesis of PD remains unclear in modern
medicine. Since the late 1960s, levodopa replacement therapy has
been used successfully to treat PD and has been recognized as a
major turning point in PD treatment. However, the long-term
application of this therapy causes side effects and the therapy
does not treat the underlying causes of PD (Del Sorbo and
Albanese, 2008). Therefore, active research for new drugs or
treatment methods targeting the protection of dopaminergic
neurons is crucial for treating PD.
In earlier studies, the application of terminal deoxynucleotidyl
transferase-mediated dUTP nick end labeling indicated that
0.6%–4.8% of dopaminergic neurons in the SN of PD patients
showed apoptosis (Mochizuki et al., 1996). Electron microscopy
showed apoptotic features, including chromatic condensation
and apoptotic bodies in dopaminergic cells (Anglade et al.,
1997). Tompkins et al. (1997) performed an ultrastructural
analysis of brain tissue autopsies from patients with PD, AD
and diffuse Lewy body disease (DLBD). They found apoptotic
bodies in the dense layer of the SN in PD and DLBD patients,
providing conclusive evidence of neuronal apoptosis in PD
and related diseases. Therefore, the reduction or suppression
of apoptosis in dopaminergic neurons is fundamental for PD
treatment.
Previous studies showed that MPTP induced PD-like
symptoms. MPTP crosses the blood-brain barrier and is
metabolized by type B monoamine oxidases in astrocytes. It
is subsequently converted to toxic MPP+, which accumulates
in the mitochondria of dopaminergic neurons through the
protein intake of the DA transporter. It thus generates excess
oxygen free radicals that inhibit complex I activity of the
mitochondrial respiratory chain and ATP synthesis. These
events further promote free radical formation and oxidative
stress reactions, and eventually lead to the degeneration and
death of dopaminergic neurons. Hence, this study used MPP+
to establish an in vitro vehicle in MES23.5 dopaminergic
neurons and MPTP to induce a vehicle mouse for mutual
verification. According to the results of the MTT assay, MPP+
significantly reduced the viability of MES23.5 cells, suggesting
that MPP+ was cytotoxic to dopaminergic neurons. The results
also demonstrated that C. tubulosa effectively enhanced the
expression of anti-apoptotic proteins and inhibited the increase
of MPP+-induced apoptosis.
PD and GDNF
GDNF is a neurotrophic factor, which was first isolated by Lin
et al. (1993). Lin et al. (1993) also showed that GDNF had specific
nutritional effects on dopaminergic neurons in the midbrain
of rats. GDNF, neurturin (NTN), persephin (PSP) and artemin
(ART) constitute the GDNF family. They are structurally similar
and functionally related secretory proteins (Kotzbauer et al.,
1996; Baloh et al., 1998; Milbrandt et al., 1998; Woodbury et al.,
1998).
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FIGURE 8 | Expression of glial cell-derived neurotrophic factor (GDNF) and its receptors, GDNF family receptor alpha (GFRα1) and Ret in different
groups of mice. The GDNF-positive cells in the SN in different treatment groups of mice (400×) (A–F). The GFRα1-positive cells in the SN (400×) (G–L). The
Ret-positive cells in the SN (400×) (M–R). (A,G,M) Negative control; (B,H,N) Control; (C,I,O) Vehicle; (D,J,P) Low-dose; (E,K,Q) Middle-dose; (F,L,R) High-dose.
Integrated optical density of GDNF-positive cells, GFRα1- and Ret-positive cells, in different treatment groups of mice (S). Protein expression of GDNF, GFRα1 and
Ret (T,U). Compare with the Vehicle: ∗∗P < 0.01; ∗P < 0.05; “n.s.” means no significance. n = 3.
The GDNF receptor consists of two components. The
first component, GFRα, is fixed to the outer membrane of
glycosylphosphatidylinositol (GPI) and anchored to the surface
of connexin. The second component is Ret protein. Research
has showed that there are four different types of GFRα: GFRα1,
GFRα2, GFRα3 and GFRα4. GFRα1 is a high affinity receptor
of GDNF (Onochie et al., 2000; Chen et al., 2001; Lindahl
et al., 2001). Ret protein is a functional receptor of GDNF. The
homodimer molecule of GDNF directly binds to GFRα1 to form
complexes and interacts with Ret, resulting in the dimerization
and activation of Ret. Due to autophosphorylation of Ret, Ret
activates several common TH signaling pathways. In the absence
of Ret protein, GDNF causes protein phosphorylation of MAPK,
PI-3 and PLC-γ, in addition to mRNA expression and functional
activity of C-fos through its receptor protein, GFRα1 (He et al.,
2008).
Studies have demonstrated that GDNF had the strongest
protective effect on dopaminergic neurons (Rangasamy
et al., 2010; Campos et al., 2012). In vehicles using MPTP
and 6-hydroxydopamine (6-OHDA) to induce damage
in dopaminergic neurons, GDNF protects dopaminergic
neuron by reducing apoptosis and promoting axonal growth
to induce stem cell differentiation (Lucas et al., 2012;
Littrell et al., 2013). Lin et al. (1993) showed that GDNF
specifically promoted viability, differentiation and axonal
growth of dopaminergic neurons to promote the uptake
of DA in neurons. The study also showed that GDNF not
only prevented acute toxicity, but also alleviated long-term
toxicity of MPP+ or 6-OHDA in dopaminergic neurons,
furthermore preventing cell death in stressed or damaged cells
(Yu et al., 2010). In addition, GDNF promoted neural stem
cell proliferation and differentiation toward dopaminergic
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FIGURE 9 | Protein expression of Bcl2 and Bax in brain tissues from different treatment groups of mice. The Bcl2 and Bax protein expression in brain
tissues (A). The column charts of Bcl2 and Bax protein expression in brain tissues (B,C). Compare with the Vehicle: ∗∗P < 0.01; ∗P < 0.05; “n.s.” means no
significance. n = 3.
neurons in the midbrain (Lindsay, 1995) to rescue dopaminergic
neurons from retrograde degeneration (Hong-Juan et al.,
2011).
Studies have shown that GDNF expression in the SN was
significantly reduced in animal vehicles (Yang et al., 2010).
This suggests that it may be one of the mechanisms of
pathogenesis in PD rats. The injection of 5–15 µg/d GDNF into
the lateral ventricle or striatum of an MPTP-induced vehicle
animal for three consecutive months promoted nigrostriatal
repair of the dopaminergic system in the vehicle animal
(Grondin et al., 2002). Studies of GDNF treatment for
a PD in animal vehicle have shown that intracerebral
injection of GDNF into different brain regions, such as
the SN, caudate nucleus and lateral ventricle, improved
movement disorders associated with PD animal models,
including decreased motor activity, muscle rigidity and tremor
(Grondin et al., 2002). However, GDNF cannot directly pass
through the blood-brain barrier. Therefore, local cerebral
injection of GDNF involves substantial risk and difficulties
in clinical application. Applications to introduce exogenous
GDNF via controlled-release microspheres, sustained-release
capsules and viral genes are still being studied (Liang et al.,
2010; Yang et al., 2010; Qiao et al., 2012). Given the
limitations of various techniques to introduce exogenous
GDNF into the brain, neuroprotective agents that promote
the release of endogenous GDNF are significant for clinical
application.
PD and C. tubulosa Nanopowder
PD is more common in middle-aged adults and the elderly. The
theory of TCM considers that PD is primarily located in the brain
and is mainly due to liver and kidney deficiency, in addition to
vital energy and blood insufficiency. According to this theory,
PD treatment should thus focus on invigorating kidney and bone
marrow. Yang et al. (2010) used randomized, double blind and
placebo-controlled clinical trials and found that combination
therapy using Madopar and kidney-tonifying recipes alleviated
the motor dysfunctions of PD patients. The treatment result was
better than a single therapy using Madopar. Treatment efficacy
of TCM monotherapy or compound prescription in PD has
been confirmed in PD animal models and clinical applications.
TCM applications for tonifying kidney and promoting blood
circulation reduced the dosage of monotherapy for PD using
Madopar. Some studies have suggested that TCM improved
symptoms of PD and protected dopaminergic neurons, which
might have been closely related to the promotion of endogenous
GDNF expression (Hong-Juan et al., 2011; Qiao et al.,
2012).
The kidney-tonifying compound used in this study,
C. tubulosa nanopowder, contained Cistanche, epimedium
and Rhizoma polygonati. Modern research suggests that the
chemical composition of Cistanche is ECH, which protects
dopaminergic neurons in the SN in the MPTP-induced PDmice,
and inhibits the reduction of DA and the DA transporter (Zhao
et al., 2010). In addition, it prevents 6-OHDA-induced reduction
in DA and protects striatal dopaminergic neurons (Chen et al.,
2007). Epimedium inhibits the activation of caspase-3 and
exerts neuroprotective roles (Liu et al., 2011). Epimedium
flavonoids effectively promote neural stem cell proliferation and
differentiation (Yao et al., 2010).
In this study, C. tubulosa nanopowder antagonized the
increase of MPP+-induced apoptosis in a dose-dependent
manner. It significantly improved TH expression in the
in vitro vehicle and had significant anti-apoptotic effects in
dopaminergic neurons. The MPTP-induced vehicle mice
showed behavioral disorders and significantly reduced TH
expression in the midbrain tissues and DA levels, which
are typical pathological features of PD. Different dosages of
C. tubulosa nanopowder shortened the stationary duration,
enhanced autonomous activities, improved behavioral
disorders, elevated DA levels in the brain and increased TH
expression in vehicles. These results suggested that C. tubulosa
nanopowder exerted protective effects in dopaminergic
neurons, thereby improving behavioral disorders of vehicles.
Different dosages of C. tubulosa nanopowder increased the
expression of GDNF protein and its receptor proteins in
the brain of vehicle mice. High-dose C. tubulosa treatment
significantly upregulated Bcl2 expression and reduced Bax
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expression, which suggested that C. tubulosa nanopowder
might promote GDNF expression and secretion in the
MPTP-damaged mouse brain. In addition, it might exert
neuroprotective effects in dopaminergic neurons and minimize
neuronal apoptosis through the neurotrophic support roles of
GDNF.
This study demonstrated that C. tubulosa nanopowder
exerted protective effects in dopaminergic neurons in both
in vitro and in vivo and increased TH expression to improve
DA content. It also improved behavioral disorders in an
MPTP-induced vehicle mice, regulated protein expression of
GDNF and its receptor proteins in the SN, and had anti-apoptotic
effects in the PDmice. The mechanism underlying clinical effects
of C. tubulosa nanopowder in PD may involve increasing the
content of endogenous GDNF in the brain and thereby reducing
the damage to dopaminergic neurons.
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